Novartis has won approval in Switzerland for the world’s first malaria drug for newborns and infants, creating a new weapon ...

The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...

Novartis has received approval for Coartem Baby, the world’s first malaria treatment specifically for newborns and young ...

The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Malaria caused 597,000 deaths worldwide in 2023, with children under 5 accounting for 76 percent of all malaria deaths in the ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

The first malaria treatment for newborns and young infants has received approval from Swiss health regulators, with eight ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...